Any current/future new fundraising through debt or equity?

Godrej Agrovet had an enabling resolution for raising ₹1,000 crores through debt, but the plan has been postponed. The company is focusing on using internal accruals and aims to reduce working capital significantly in the current quarter. They may now need only ₹500-600 crores instead of the full ₹1,000 crores initially considered. No immediate new equity fundraising was mentioned in the provided information. The management is keeping a close watch on the funding requirements, especially for Astec LifeSciences, but no fresh decisions have been made yet.

Any current/future capex/capital investment/strategic investment?

Godrej Agrovet has done ₹161 crores of CAPEX consolidated in the first nine months of FY25. They expect to end FY25 with about ₹220 crores of CAPEX. A similar CAPEX plan is in place for FY26. In pet food, the pilot plant will be ready in a few weeks for R&D and marketing trials. The full-scale pet food plant (35,000 to 40,000 tons per annum) is expected by end of FY26. Management is considering internal accruals and plans to reduce working capital; the previously planned ₹1,000 crores debt raise has been postponed and may be reduced to ₹500-600 crores. They are also thinking about simplifying

Future growth expectations in sales/revenue/volumes?

Astec CDMO business is expected to see 30-35% growth in FY26 with confirmed orders, though FY25 was flat due to order postponements. Enterprise business volume growth is cautiously expected at 14-16% in FY26 with a focus on positive contribution margins. Animal Feed EBIT per ton is expected to remain sustainable at ₹1,800-2,000 in FY26, supported by R&D and cost initiatives. Dairy segment showed 1.7% revenue growth in first nine months FY25 with an expected improvement in Q4 fueled by the season and price increases. Palm Oil division had strong performance due to favorable external fac

Future growth expectations in earnings/operating earnings/profits/EPS?

Animal Feed segment expects sustained EBIT per ton of ₹1,800 to ₹2,000 in FY26, backed by R&D and cost initiatives. Q4 EBIT per ton anticipated over ₹2,100. Dairy business shows volume recovery; Q4 and FY26 expected to improve with stable milk procurement costs and increased direct farmer procurement (target 75%-80%). Poultry business is shifting strategically towards branded segments (RGC and Yummiez), reducing live birds share from 41% to 26%, improving profitability. Palm Oil segment benefitted from favorable government policies and high international prices; however, only 20% price b

Current/ Expected Orderbook/ Pending Orders?

Astec LifeSciences' CDMO business currently has confirmed orders/orders backed by purchase orders (POs). Visibility for FY26 CDMO growth is around 30% to 35%, with potential to reach 40%, pending one or two customer confirmations. Management emphasized reliance only on confirmed orders for forecasts due to postponements or cancellations in bad times. FY25 CDMO growth expected to be flat (no growth) due to market inventory buildup and delays. The company takes a conservative approach; only orders already secured and confirmed are included in guidance. New CDMO orders or projects are in the pipe

IN US

Sale is live|00:00:00left today

Godrej Agrovet LtdQ4 FY26Food Products

Godrej Agrovet Ltd Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹566P/E: 22.1Market Cap: ₹11.0K CrSector: Food Products

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Astec CDMO business is expected to see 30-35% growth in FY26 with confirmed orders, though FY25 was flat due to order postponements.
→Enterprise business volume growth is cautiously expected at 14-16% in FY26 with a focus on positive contribution margins.
→Animal Feed EBIT per ton is expected to remain sustainable at ₹1,800-2,000 in FY26, supported by R&D and cost initiatives.
→Dairy segment showed 1.7% revenue growth in first nine months FY25 with an expected improvement in Q4 fueled by the season and price increases.
→Palm Oil division had strong performance due to favorable external factors, with potential for continuation but also affected by global factors.
→Crop protection segments experience volume fluctuations; focus on cotton herbicide expected to show good numbers.
→Direct milk procurement expected to increase from current ~65% to 75-80%, improving cost efficiency and volumes.
→Volume growth across animal feed segments is healthy, with expectations of sustained improvements in FY26.

Margin guidance

Category 3

→Animal Feed segment expects sustained EBIT per ton of ₹1,800 to ₹2,000 in FY26, backed by R&D and cost initiatives. Q4 EBIT per ton anticipated over ₹2,100.
→Dairy business shows volume recovery; Q4 and FY26 expected to improve with stable milk procurement costs and increased direct farmer procurement (target 75%-80%).
→Poultry business is shifting strategically towards branded segments (RGC and Yummiez), reducing live birds share from 41% to 26%, improving profitability.
→Palm Oil segment benefitted from favorable government policies and high international prices; however, only 20% price benefit accrues to the company.
→Astec LifeSciences CDMO business had a flat growth in FY25 but expects 30%-35% growth in FY26 with confirmed orders, cautious on order postponements.
→Overall, cautious but optimistic outlook with focused volume growth, margin expansion, and cost control aiming to drive earnings and profitability improvements through FY26.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Godrej Agrovet had an enabling resolution for raising ₹1,000 crores through debt, but the plan has been postponed.
→The company is focusing on using internal accruals and aims to reduce working capital significantly in the current quarter.
→They may now need only ₹500-600 crores instead of the full ₹1,000 crores initially considered.
→No immediate new equity fundraising was mentioned in the provided information.
→The management is keeping a close watch on the funding requirements, especially for Astec LifeSciences, but no fresh decisions have been made yet.

Order book

→Astec LifeSciences' CDMO business currently has confirmed orders/orders backed by purchase orders (POs).
→Visibility for FY26 CDMO growth is around 30% to 35%, with potential to reach 40%, pending one or two customer confirmations.
→Management emphasized reliance only on confirmed orders for forecasts due to postponements or cancellations in bad times.
→FY25 CDMO growth expected to be flat (no growth) due to market inventory buildup and delays.
→The company takes a conservative approach; only orders already secured and confirmed are included in guidance.
→New CDMO orders or projects are in the pipeline, with efforts ongoing to expand customer base in Europe and globally.

Capex plans

Yes

→Godrej Agrovet has done ₹161 crores of CAPEX consolidated in the first nine months of FY25.
→They expect to end FY25 with about ₹220 crores of CAPEX.
→A similar CAPEX plan is in place for FY26.
→In pet food, the pilot plant will be ready in a few weeks for R&D and marketing trials.
→The full-scale pet food plant (35,000 to 40,000 tons per annum) is expected by end of FY26.
→Management is considering internal accruals and plans to reduce working capital; the previously planned ₹1,000 crores debt raise has been postponed and may be reduced to ₹500-600 crores.
→They are also thinking about simplifying the company structure to enhance investor visibility and value.

How does Godrej Agrovet Ltd rank vs peers in Food Products?

Pro feature

1Godrej Agrovet Ltd

Rev 3Mar 3

See full Food Products sector rankings

Want more stocks like Godrej Agrovet Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio